PMID- 28298231
OWN - NLM
STAT- MEDLINE
DCOM- 20171128
LR  - 20220331
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 10
IP  - 1
DP  - 2017 Mar 15
TI  - Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter 
      real-world study in China.
PG  - 69
LID - 10.1186/s13045-017-0439-6 [doi]
LID - 69
AB  - The efficacy and safety of chidamide, a new subtype-selective histone deacetylase 
      (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, 
      and chidamide has been approved by the China Food and Drug Administration (CFDA) 
      as a treatment for relapsed or refractory peripheral T cell lymphoma (PTCL). This 
      study sought to further evaluate the real-world utilization of chidamide in 383 
      relapsed or refractory PTCL patients from April 2015 to February 2016 in mainland 
      China. For patients receiving chidamide monotherapy (n = 256), the overall 
      response rate (ORR) and disease control rate (DCR) were 39.06 and 64.45%, 
      respectively. The ORR and DCR were 51.18 and 74.02%, respectively, for patients 
      receiving chidamide combined with chemotherapy (n = 127). For patients receiving 
      chidamide monotherapy and chidamide combined with chemotherapy, the median 
      progression-free survival (PFS) was 129 (95% CI 82 to 194) days for the 
      monotherapy group and 152 (95% CI 93 to 201) days for the combined therapy group 
      (P = 0.3266). Most adverse events (AEs) were of grade 1 to 2. AEs of grade 3 or 
      higher that occurred in >/=5% of patients receiving chidamide monotherapy included 
      thrombocytopenia (10.2%) and neutropenia (6.2%). For patients receiving chidamide 
      combined with chemotherapy, grade 3 to 4 AEs that occurred in >/=5% of patients 
      included thrombocytopenia (18.1%), neutropenia (12.6%), anemia (7.1%), and 
      fatigue (5.5%). This large real-world study demonstrates that chidamide has a 
      favorable efficacy and an acceptable safety profile for refractory and relapsed 
      PTCL patients. Chidamide combined with chemotherapy may be a new treatment choice 
      for refractory and relapsed PTCL patients but requires further investigation.
FAU - Shi, Yuankai
AU  - Shi Y
AD  - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on 
      Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      100021, China. syuankaipumc@126.com.
FAU - Jia, Bo
AU  - Jia B
AD  - Peking University Cancer Hospital and Institute, Beijing, China.
FAU - Xu, Wei
AU  - Xu W
AD  - Jiangsu Province Hospital, Nanjing, China.
FAU - Li, Wenyu
AU  - Li W
AD  - Guangdong General Hospital, Guangzhou, China.
FAU - Liu, Ting
AU  - Liu T
AD  - West China Hospital, Sichuan University, Chengdu, China.
FAU - Liu, Peng
AU  - Liu P
AD  - Zhongshan Hospital, Shanghai, China.
FAU - Zhao, Weili
AU  - Zhao W
AD  - Shanghai Ruijin Hospital, Shanghai, China.
FAU - Zhang, Huilai
AU  - Zhang H
AD  - Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
FAU - Sun, Xiuhua
AU  - Sun X
AD  - The Second Hospital of Dalian Medical University, Dalian, China.
FAU - Yang, Haiyan
AU  - Yang H
AD  - Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Zhang, Xi
AU  - Zhang X
AD  - Xinqiao Hospital, Third Military Medical University, Chongqing, China.
FAU - Jin, Jie
AU  - Jin J
AD  - The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
FAU - Jin, Zhengming
AU  - Jin Z
AD  - The First Affiliated Hospital of Soochow University, Suzhou, China.
FAU - Li, Zhiming
AU  - Li Z
AD  - Sun Yat-Sen University Cancer Center, Guangzhou, China.
FAU - Qiu, Lugui
AU  - Qiu L
AD  - Hematology Institute and Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Tianjin, China.
FAU - Dong, Mei
AU  - Dong M
AD  - Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on 
      Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, 
      Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 
      100021, China.
FAU - Huang, Xiaobing
AU  - Huang X
AD  - Sichuan Provincial People's Hospital, Chengdu, China.
FAU - Luo, Yi
AU  - Luo Y
AD  - Hunan Cancer Hospital, Changsha, China.
FAU - Wang, Xiaodong
AU  - Wang X
AD  - Sichuan Provincial People's Hospital, Chengdu, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Shandong Provincial Hospital, Jinan, China.
FAU - Wu, Jianqiu
AU  - Wu J
AD  - Jiangsu Cancer Hospital, Nanjing, China.
FAU - Xu, Jingyan
AU  - Xu J
AD  - Nanjing Drum Tower Hospital, Nanjing, China.
FAU - Yi, Pingyong
AU  - Yi P
AD  - Hunan Cancer Hospital, Changsha, China.
FAU - Zhou, Jianfeng
AU  - Zhou J
AD  - Tongji Hospital, Wuhan, China.
FAU - He, Hongming
AU  - He H
AD  - Fujian Provincial Cancer Hospital, Fuzhou, China.
FAU - Liu, Lin
AU  - Liu L
AD  - The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
FAU - Shen, Jianzhen
AU  - Shen J
AD  - Union Hospital, Fujian Medical University, Fuzhou, China.
FAU - Tang, Xiaoqiong
AU  - Tang X
AD  - The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
FAU - Wang, Jinghua
AU  - Wang J
AD  - General Hospital of Nanjing Military Region, Nanjing, China.
FAU - Yang, Jianmin
AU  - Yang J
AD  - Changhai Hospital, Shanghai, China.
FAU - Zeng, Qingshu
AU  - Zeng Q
AD  - The First Affiliated Hospital of Anhui Medical University, Hefei, China.
FAU - Zhang, Zhihui
AU  - Zhang Z
AD  - Sichuan Cancer Hospital and Institute, Chengdu, China.
FAU - Cai, Zhen
AU  - Cai Z
AD  - The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
FAU - Chen, Xiequn
AU  - Chen X
AD  - Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
FAU - Ding, Kaiyang
AU  - Ding K
AD  - Anhui Provincial Hospital, Hefei, China.
FAU - Hou, Ming
AU  - Hou M
AD  - QiLu Hospital of Shandong University, Jinan, China.
FAU - Huang, Huiqiang
AU  - Huang H
AD  - Sun Yat-Sen University Cancer Center, Guangzhou, China.
FAU - Li, Xiaoling
AU  - Li X
AD  - Liaoning Cancer Hospital and Institute, Dalian, China.
FAU - Liang, Rong
AU  - Liang R
AD  - Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
FAU - Liu, Qifa
AU  - Liu Q
AD  - Nanfang Hospital, Southern Medical University, Guangzhou, China.
FAU - Song, Yuqin
AU  - Song Y
AD  - Peking University Cancer Hospital and Institute, Beijing, China.
FAU - Su, Hang
AU  - Su H
AD  - The 307th Hospital of Chinese People's Liberation Army, Beijing, China.
FAU - Gao, Yuhuan
AU  - Gao Y
AD  - Fourth Hospital of Hebei Medical University (Tumor Hospital of Hebei Province), 
      Shijiazhuang, China.
FAU - Liu, Lihong
AU  - Liu L
AD  - Fourth Hospital of Hebei Medical University (Tumor Hospital of Hebei Province), 
      Shijiazhuang, China.
FAU - Luo, Jianmin
AU  - Luo J
AD  - The Second Hospital of Hebei Medical University, Shijiazhuang, China.
FAU - Su, Liping
AU  - Su L
AD  - Shanxi Provincial Cancer Hospital, Taiyuan, China.
FAU - Sun, Zimin
AU  - Sun Z
AD  - Anhui Provincial Hospital, Hefei, China.
FAU - Tan, Huo
AU  - Tan H
AD  - The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
FAU - Wang, Huaqing
AU  - Wang H
AD  - Tianjin People's Hospital, Tianjin, China.
FAU - Wang, Jingwen
AU  - Wang J
AD  - Beijing Tongren Hospital, Beijing, China.
FAU - Wang, Shuye
AU  - Wang S
AD  - The First Affiliated Hospital of Harbin Medical University, Harbin, China.
FAU - Zhang, Hongyu
AU  - Zhang H
AD  - Peking University Shenzhen Hospital, Shenzhen, China.
FAU - Zhang, Xiaohong
AU  - Zhang X
AD  - The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 
      China.
FAU - Zhou, Daobin
AU  - Zhou D
AD  - Peking Union Medical College Hospital, Beijing, China.
FAU - Bai, Ou
AU  - Bai O
AD  - The First Hospital of Jilin University, Changchun, China.
FAU - Wu, Gang
AU  - Wu G
AD  - Wuhan Union Hospital of China, Wuhan, China.
FAU - Zhang, Liling
AU  - Zhang L
AD  - Wuhan Union Hospital of China, Wuhan, China.
FAU - Zhang, Yizhuo
AU  - Zhang Y
AD  - Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
LA  - eng
PT  - Letter
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20170315
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Aminopyridines)
RN  - 0 (Benzamides)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 87CIC980Y0 
      (N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminopyridines/*administration & dosage/adverse effects/therapeutic use
MH  - Anemia/chemically induced
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Benzamides/*administration & dosage/adverse effects/therapeutic use
MH  - China
MH  - Disease-Free Survival
MH  - Fatigue/chemically induced
MH  - Female
MH  - Histone Deacetylase Inhibitors/therapeutic use
MH  - Humans
MH  - Lymphoma, T-Cell, Peripheral/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neutropenia/chemically induced
MH  - Recurrence
MH  - Remission Induction/methods
MH  - Salvage Therapy/adverse effects/methods
MH  - Thrombocytopenia/chemically induced
MH  - Young Adult
PMC - PMC5351273
OTO - NOTNLM
OT  - Chemotherapy
OT  - Chidamide
OT  - Peripheral T cell lymphoma
OT  - Treatment
EDAT- 2017/03/17 06:00
MHDA- 2017/11/29 06:00
PMCR- 2017/03/15
CRDT- 2017/03/17 06:00
PHST- 2017/01/16 00:00 [received]
PHST- 2017/03/07 00:00 [accepted]
PHST- 2017/03/17 06:00 [entrez]
PHST- 2017/03/17 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/03/15 00:00 [pmc-release]
AID - 10.1186/s13045-017-0439-6 [pii]
AID - 439 [pii]
AID - 10.1186/s13045-017-0439-6 [doi]
PST - epublish
SO  - J Hematol Oncol. 2017 Mar 15;10(1):69. doi: 10.1186/s13045-017-0439-6.